Teva Pharmaceutical Industries Market Forecasts & Analysis 2007-2012

Table of Contents

1 Executive Summary: Teva Pharmaceutical Industries 2007-2012

2 An Introduction to Teva Pharmaceutical Industries

• 2.1 Teva is a Top 20 Pharmaceutical Company and Global Leader in Generics
• 2.2 Teva is Listed on Various Stock Exchanges, Including NASDAQ
• 2.3 Teva Achieved Sales of $8.4bn in 2006
  • 2.3.1 Most of Teva' s Sales are In North America
  • 2.3.2 Most of Teva' s Sales Are Generated by the Pharmaceuticals Division
• 2.4 Vision and Core Values in Teva
• 2.5 Human Pharmaceuticals Division
  • 2.5.1 Teva Produces Generic Drugs in All Major Therapeutic Categories
  • 2.5.2 Teva Markets and Develops Innovative Drugs for Specialised Markets
  • 2.5.3 The Pharmaceuticals Division Contributes 90% of Teva' s Revenues
  • 2.5.4 Copaxone (glatiramer acetate)
  • 2.5.5 Azilect (rasagiline)
• 2.6 Active Pharmaceutical Ingredients (API) Division
• 2.7 Generic Pharmaceuticals - a Comprehensive Portfolio
  • 2.7.1 Teva USA
  • 2.7.2 Teva Generics in Europe
• 2.8 Veterinary Products
• 2.9 Key Acquisitions by Teva
  • 2.9.1 Acquisition of Ivax Corporation in January 2006
  • 2.9.2 Sicor became a wholly owned subsidiary of Teva in January 2004
  • 2.9.3 Acquisition of Novopharm
• 2.10 A Brief History of Teva
  • 2.10.1 Formation of the Company at the Start of the Twentieth Century
  • 2.10.2 Growth During the WWII and the Establishment of the State of Israel during 1940s & 50s
  • 2.10.3 Consolidation During the 1960s & 70s - Establishment of Teva Pharmaceutical Industries Ltd
  • 2.10.4 Further Acquisitions and Dominance During the 1980s
  • 2.10.5 1990s: Expanding Presence Worldwide
• 2.11 Key Events in the History of Teva Pharmaceuticals USA

3 Teva Pharmaceutical Industries Is Responding To Challenges and Opportunities in The Market Through Ambitious Corporate Strategy

• 3.1 The World Pharmaceutical Market Continues to Grow, But Faces Mounting Challenges
• 3.2 The Continuing Success of International Pharmaceutical Companies is Dependent Upon Important Drivers and Restraints
• 3.3 Companies Are Gradually Changing Their Strategic Focus to Overcome Challenges in the Worldwide Market
• 3.4 Reduced Efficiencies in R&D Result in Concerns Over Thinning Pipelines
• 3.5 Driving and Restraining Forces Acting Upon Teva Pharmaceutical Industries
  • 3.5.1 A SWOT Analysis for Teva Pharmaceutical Industries, 2007-2012
• 3.6 Teva Has a Focussed Strategy To Cope with Market Conditions and Opportunities
  • 3.6.1 Teva Has Clear Strategic Objectives for the Years Ahead
  • 3.6.2 Strategic Focus Explains Teva' s Recent Growth
  • 3.6.3 Teva is Moving Towards Higher-Value Innovative Molecules
• 3.7 Teva' s Sales Increased Spectacularly in 2006 after Ivax Acquisition
  • 3.7.1 Ivax Acquisition and Generics Launches Boosted Growth in 2006
  • 3.7.2 All The Principal Geographical Regions Exhibited Strong Growth During 2006
  • 3.7.3 Pharmaceuticals Division was a Strong Driver of Sales Growth in 2006
• 3.8 Teva Will Increase its Sales Substantially Between 2006 and 2012
  • 3.8.1 From 2007-2012 Sales Will Be Driven By Strong Growth in The Pharmaceuticals Division
  • 3.8.2 Teva Can Remain at the Forefront of the Global Generics Industry and Continue to be a Strong Niche Pharmaceutical Company
  • 3.8.3 Cost Containment in Europe Provides Major Opportunities for Teva
• 3.9 Teva Reported Strong Results for the First Quarter of 2007
• 3.10 Generics Companies Such as Teva Must Expand Cautiously, With Valid Strategic Justification
  • 3.10.1 Strategic Vigilance is Required
  • 3.10.2 Generics Companies Use Acquisitions to Access New Markets - With Teva Extending Its Geographic and Technological Reach in That Manner
  • 3.10.3 Teva Has Expanded for Justifiable Strategic Reasons
  • 3.10.4 2007 Will Provide Major Opportunities for Teva, As Will the Period 2010-2012
  • 3.10.5 Teva Recently Expanded Its Manufacturing Facilities in Jerusalem
• 3.11 Teva Has Benefited from a Vigorous Acquisitions Strategy
  • 3.11.1 Teva Took Advantage of The Hatch-Waxman Act of 1984
  • 3.11.2 Important Acquisitions in Recent Years - Culminating in the Incorporation of Ivax - Have Benefited Teva Immensely
  • 3.11.3 Teva-Ivax Marked the Second Major Generics Acquisition in Recent Times
  • 3.11.4 Differentiation in the Market is Vital to the Continuing Success of Teva - In That Way Teva Can Withstand Downward Pressure On Prices in Conventional Generic Drugs
  • 3.11.5 Incorporation of Ivax in January 2006 Gave Teva Pre-Eminence in the Expanding Global Generics Market
  • 3.11.6 Acquisition of acquisition of Dorom Srl in 2004
  • 3.11.7 Teva and US Company Sicor Signed a Definitive Agreement in 2004
  • 3.11.8 Acquisition of Bayer' s and Merck & Co' s French Generics Units in 2002
  • 3.11.9 2000 Was Marked by Acquisitions of Novopharm and Human Serum & Pharma
  • 3.11.10 Copley Pharmaceutical Institute for Drug Research Acquired in 1999
  • 3.11.11 The 1990s Saw Other Acquisitions by Teva
• 3.12 Teva Makes Good Use of International Subsidiaries
  • 3.12.1 Most of Teva' s Sales Revenues Are Generated in the US
  • 3.12.2 Europe Also Achieved a Significant Contribution to Revenue
  • 3.12.3 Teva Has Dominance in The US Generics Market After Incorporating Ivax
  • 3.12.4 Significant Global Expansion Since Late 1990s
• 3.13 In Common With Other Generics Companies, Teva Faces Litigation Over Patent-Related Issues
  • 3.13.1 Paragraph IV Certification
  • 3.13.2 Bayer Filed Lawsuit Against Teva Over Avelox
  • 3.13.3 Teva Provided Update On Litigation Over Generic Celebrex
  • 3.13.4 Agreement With Biovail And Anchen Regarding Generic Wellbutrin XL
  • 3.13.5 Settlement Over Cephalon' s Provigil
  • 3.13.6 Exclusivity for Generic Zocor Not Attained But Strong Revenues for Teva' s Generic Expected
  • 3.13.7 Teva in Litigation with Abbott
  • 3.13.8 Teva Will Continue to Supply Generic Oxycodone Throughout 2007
  • 3.13.9 Teva Filed Patent Infringement Complaints Regarding Sertraline Hydrochloride
  • 3.13.10 Agreement With Pfizer Regarding Idarubicin, Azithromycin, And Epirubicin
• 3.14 Teva: Collaborations and Licensing
  • 3.14.1 Abitren/Diclofenac Q
  • 3.14.2 Azilect
  • 3.14.3 Budeprion SR
  • 3.14.4 Copaxone
  • 3.14.5 Diltiazem
  • 3.14.6 Nifedipine ER/Nifedipine Teva
  • 3.14.7 Previfem/Tri-Previfem
  • 3.14.8 Purinethol
  • 3.14.9 Purinethol
  • 3.14.10 Quinapril Teva
  • 3.14.11 Verapamil
  • 3.14.12 Zavesca
• 3.15 ProNeuron Biotechnologies Filed to Annul License Agreement with Teva Over Clinical Trials

4 Pharmaceuticals Division

• 4.1 The Pharmaceuticals Division Will Yield Strong Growth, Strongly Driving Overall Corporate Revenues
  • 4.1.1 Teva Benefited from an Ambitious Strategy of Acquisition
  • 4.1.2 Teva Had Over 150 Products Awaiting FDA Approval at the End of 2006
  • 4.1.3 Promising First Quarter Results for 2007
• 4.2 Copaxone - Teva' s First Innovative Drug to Receive FDA Approval
  • 4.2.1 Steady Revenue Increase Expected for Teva' s Flagship Product
  • 4.2.2 Copaxone Faces Present and Future Competitive Challenges in the Market
  • 4.2.3 Copaxone Was Originally Licensed from the Weizmann Institute of Science
  • 4.2.4 Copaxone is the Subject of Promising Clinical Studies
  • 4.2.5 Lifecycle Management of Copaxone: Teva Makes Good Use of Collaborations
• 4.3 Azilect - Teva' s Recently Launched Innovative Product
  • 4.3.1 Azilect is Currently In a Period of High Early Growth
  • 4.3.2 Azilect is a Potent Agent for Early and Advanced Parkinson' s Disease
  • 4.3.3 Azilect Benefits from Convenient Dosing
  • 4.3.4 Azilect is Co-Marketed in Europe by Lundbeck and Teva
  • 4.3.5 Co-Development of Azilect with Eisai
  • 4.3.6 Phase IV Post-Marketing Study to Investigate Risk of Melanoma
  • 4.3.7 Azilect May Have Potential in the Early Treatment of Parkinson' s
  • 4.3.8 Competition for Azilect
  • 4.3.9 Azilect Has Performed Well in Clinical Studies
• 4.4 Teva Has a Diverse Generics Portfolio
  • 4.4.1 Revenues from Generics Spread Over Many Products
  • 4.4.2 Teva Receives First US Approval For Generic Uniretic Tablets
  • 4.4.3 Teva Receives Approval For Generic Dostinex Tablets
  • 4.4.4 Teva Announced Approval of Alprazolam ER Tablets
  • 4.4.5 Teva Announced Its Launch of Generic Wellbutrin XL Tablets Through Agreement With Anchen And IMPAX
  • 4.4.6 Teva Announced Tentative Approval Of Sumatriptan Succinate Tablets
  • 4.4.7 Teva Receives Approval for Generic Focalin Tablets
  • 4.4.8 Teva Announced Agreement with Pfizer Regarding Idarubicin, Azithromycin, And Epirubicin
  • 4.4.9 Launch of Generic Zoloft by Teva
  • 4.4.10 Final Approval of Venlafaxine HCL Tablets
  • 4.4.11 Final Approval of Meloxicam Tablets
  • 4.4.12 Tentative Approval of Generic Lotrel
  • 4.4.13 Approval of Generic Zocor
  • 4.4.14 Teva Received First FDA Approval for Generic Proscar Tablets
  • 4.4.15 Tentative Approval of Losartan Potassium & Hydrochlorothiazide Tablets
  • 4.4.16 Tentative Approval for Generic Cozaar Tablets
  • 4.4.17 Tentative Approval of Simvastatin Tablets
  • 4.4.18 Approval of Generic Lexapro Tablets
• 4.5 The Integration of Ivax' s Operations Greatly Increased Teva' s Strengths in Respiratory Drugs
• 4.6 Acquisition of Ivax is a Major Coup for Teva
  • 4.6.1 Ivax Acquisition Brought Expertise in Respiratory Field in Particular
  • 4.6.2 As a Condition of the Acquisition, Teva and Ivax Had To Divest Some Products in US Market
• 4.7 Teva is Active in OTC Products
  • 4.7.1 OTC Products Part of Pharmaceuticals Division
  • 4.7.2 Out-Licensing to Perrigo
  • 4.7.3 Zirtek (cetirizine) Approval Delayed

5 Active Pharmaceutical Ingredients

• 5.1 Active Pharmaceutical Ingredients Division Will Show Steady Growth, Playing a Supporting Role
• 5.2 Teva' s API Division is a Major Supplier to the Global Pharmaceutical Industry
• 5.3 Active Pharmaceutical Ingredients Division Will Benefit from Expanding Global Pharmaceutical Market
• 5.4 Acquisition of Sicor Brought Valuable Expertise and Capacity in the Production of APIs
• 5.5 Teva Prides itself on its Technological Capabilities in API Production
• 5.6 Active Pharmaceutical Ingredients Achieved Similar Growth in Q1 2007 as in Q1 of 2006
• 5.7 Ivax Acquisition Has Brought Another 30 APIs to Teva' s Portfolio
• 5.8 Teva' s Expansion into the Japanese API Market in 2006
• 5.9 Teva Produces APIs Internationally
• 5.10 Visiongain Concludes that Teva Will Remain at the Forefront of API Supply and Custom Pharmaceutical Manufacturing Throughout the Forecast Period 2007-2012

6 Pipeline Developments in Teva

• 6.1 Teva is Conducting R&D in Important Therapeutic Areas
• 6.2 Teva' s Investment in R&D Has Been Rising in Recent Years
• 6.3 As a Leading Generic Producer Teva Has Progressed into Innovative Research & Development
• 6.4 Teva Has a Very Strong Generics Pipeline in Addition to Innovative Developments
  • 6.4.1 R&D Focussed on Multiple Sclerosis, Autoimmune Diseases, Neurology and Oncology
  • 6.4.2 Teva R&D is Concentrated in Three Divisions
  • 6.4.3 Generic and Innovative Pipelines Are Strong - Ivax Acquisition Paying Off
• 6.5 Antineoplastics/Immunomodulating Agents
  • 6.5.1 Stemex Cell Therapy
  • 6.5.2 HMN 214
  • 6.5.3 EDRATIDE (TV 4710)
  • 6.5.4 SAIK-MS
  • 6.5.5 LMB 9
  • 6.5.6 Cervene (TP 38)
• 6.6 Central Nervous System Agents
  • 6.6.1 Citicoline (IP 302)
  • 6.6.2 Cladribine (NSC 105014F)
  • 6.6.3 Fampridine-SR
  • 6.6.4 Ladostigil
  • 6.6.5 Valrocemide
• 6.7 Genitourinary System/Sex Hormones
• 6.8 Respiratory System Agents
  • 6.8.1 Respicort
  • 6.8.2 Other Agents in Development
• 6.9 Licensing Deal With Vaccinex for Monoclonal Antibody
• 6.10 Teva Collaborates on Protalix' s recombinant plant cell expression technology
• 6.11 Teva And Procognia (Israel) Ltd. Sign an Exclusive Collaboration Agreement for the Development of Biopharmaceuticals

7 Conclusions

• 7.1 Teva is a Top-20 Pharmaceutical Company with a Diverse Portfolio of Generic and Innovative Products
• 7.2 Ivax Acquisition and Generics Launches Boosted Growth in 2006
• 7.3 Sales in Teva are Dominated by the Pharmaceuticals Division
• 7.4 From 2007-2012 Sales Will Be Driven By Strong Growth in The Pharmaceuticals Division
• 7.5 Generic and Innovative Pipelines Are Strong
• 7.6 Teva Can Remain at the Forefront of the Global Generics Industry and Continue to be a Strong Niche Pharmaceutical Company With Impressive Sales Worldwide

Appendices

• Appendix 1: Major Drugs Facing Patent Expiry in the US, 2004-2009
• Appendix 2: About Visiongain
• Appendix 3: Visiongain Report Evaluation Form

List of Tables

• Table 2.1 Top 20 Global Pharmaceutical Companies, 2005
• Table 2.2 Teva Net Sales and Income, 2002-2006
• Table 2.3 Teva Subsidiaries, 2006
• Table 2.4 Sales ($m) by Geographical Area, 2004-2006
• Table 2.5 Sales ($m) by Business Division, 2004-2006
• Table 2.6 Major Events in Teva USA' s History
• Table 3.1 Revenue Generation ($bn) by the World Pharmaceutical Industry, 2000-2006
• Table 3.2 A SWOT Chart for Teva, 2007-2012
• Table 3.3 Teva - Main Financials* ($m), 2005 and 2006
• Table 3.4 Sales ($m) by Geographical Region, 2006
• Table 3.5 Sales ($m) by Division, 2006
• Table 3.6 Teva Sales ($m) by Division and Total Sales, 2006-2012
• Table 3.7 Contribution (%) of Total Sales by Division, 2006 and 2012
• Table 3.8 Teva Pharmaceutical Sales by Geographical Region and Leading National Markets, June 2005 to June 2006
• Table 4.1 Pharmaceuticals Divisional Sales ($m), 2006-2012
• Table 4.2 Copaxone and Azilect Sales ($m), 2006-2012
• Table 4.3 Copaxone and Azilect Contribution to Sales (%), 2006-2012
• Table 4.4 Copaxone Sales ($m), 2006-2012
• Table 4.5 Sales ($m), 2006-2012
• Table 4.6 Principal Therapeutic Products Manufactured by Teva, 2006
• Table 4.7 Teva Pharmaceuticals: Top Five Therapeutic Classes, 2005-2006
• Table 4.8 Pharmaceuticals: Leading International Products, 2005-2006
• Table 5.1 Active Pharmaceutical Ingredients Divisional Sales ($m), 2006-2012
• Table 6.1 R&D Investment by Teva, 2002-2006
• Table 6.2 Antineoplastics/Immunomodulating Agents Pipeline
• Table 6.3 Central Nervous System Agents
• Table 6.4 Genitourinary System/Sex Hormones
• Table 6.5 Respiratory System Agents
• Table 6.6 Other Agents in Development
• Table 7.1 Teva Sales ($m) by Division and Total Sales, 2006-2012

List of Figures

• Figure 2.1 Teva Net Sales, 2002-2006
• Figure 2.2 Teva Net Income, 2002-2006
• Figure 2.3 Sales ($m) by Geographical Area, 2004-2006
• Figure 2.4 Sales ($m) by Business Division, 2004-2006
• Figure 2.5 Teva Employee Numbers, 2005 & 2006
• Figure 3.1 Revenue Generation ($bn) by the World Pharmaceutical Industry, 2000-2006
• Figure 3.2 Teva - Main Financials* ($m), 2005 and 2006
• Figure 3.3 Sales ($m) by Geographical Region, 2006
• Figure 3.4 Contribution (%) of Sales by Geographical Region, 2006
• Figure 3.5 Sales ($m) by Division, 2006
• Figure 3.6 Contribution (%) of Sales by Division, 2006
• Figure 3.7 Teva Corporate Sales ($m), 2006-2012
• Figure 3.8 Teva Sales ($m) by Division and Total Sales, 2006-2012
• Figure 3.9 Sales ($m) by Division and Total Sales ($m), 2006 & 2012
• Figure 3.10 Contribution (%) of Total Sales by Division, 2012
• Figure 3.11 Teva Pharmaceutical Sales by Geographical Region and Leading Countries, June 2005 to June 2006
• Figure 4.1 Pharmaceutical Division Sales ($m), 2006-2012
• Figure 4.2 Copaxone and Azilect Sales ($m), 2006-2012
• Figure 4.3 Copaxone and Azilect: Relative Contributions (%) to Teva Sales, 2006 and 2012
• Figure 4.4 Copaxone Sales ($m), 2006-2012
• Figure 4.5 Azilect Revenues ($m), 2006-2012
• Figure 5.1 Active Pharmaceutical Ingredients Division Sales ($m), 2006-2012
• Figure 6.1 R&D Investment by Teva, 2002-2006
• Figure 7.1 Teva - Main Financials* ($m), 2005 and 2006
• Figure 7.2 Teva Sales ($m) by Division and Total Sales, 2006-2012

Organisations Listed

• Abbott
• Acorda
• Actelion
• Active Biotech
• Alpharma
• Amgen
• Anchen Pharmaceuticals
• Andrx Corp
• APS Berk
• AstraZeneca
• AutoImmune
• Barr Pharmaceuticals
• Bayer Healthcare AG
• Bayer Pharmaceuticals Corporation
• Biocraft Laboratories
• Biogal
• Biogen Idec
• BioMS Medical Corp
• Biosintetica
• Biovail Corporation
• Biovail Laboratories International
• Boehringer Ingelheim
• Braintree
• Bristol-Myers Squibb
• Celltech Group
• Cephalon
• Cipla
• Copley Pharmaceutical Inc
• Daiichi Sankyo
• Dan Family Holdings
• Dorom Srl
• Dr. Reddy' s Laboratories
• Eisai
• Elan
• Eli Lilly
• Ferrer
• Forest Laboratories
• GamidaCell
• Gedeon Richter
• GlaxoSmithKline
• GRY-Pharm
• Hemispherx Biopharma
• Hoechst Corporation
• Honeywell International
• Human Serum & Pharmaceutical Manufacturing
• Impax Laboratories
• Indevus
• Indevus
• Industrie Chimiche Italiane SpA
• Ivax Corporation
• JK Drugs & Pharmaceuticals
• JK Industries
• Johnson & Johnson
• Lek
• MediciNova
• Merck & Co
• Merck KGaA
• Mylan
• Nippon Shinyaku
• Novartis
• NS Pharma
• OPG Group
• Ortho Biotech
• Oxford GlycoSciences
• Par Pharmaceutical
• Perrigo
• Pfizer
• Pharmachemie
• Pharmachemie B.V.
• Pharmachemie NV
• Pharmacia
• PharmaFrontiers
• Procognia
• ProNeuron Biotechnologies
• Protalix Biotherapeutics
• Purdue Frederick Company
• Ranbaxy
• Rhone-Poulenc Rorer
• Roche
• Sandoz
• Schwartz Pharma
• Sanofi-Aventis
• Schering Plough
• Schwarz Pharma
• Serono
• Sicor
• Sigma-Tau
• Takeda
• Teva Pharmaceutical Industries
• Tianjin Hualida Biotechnology Co
• UCB
• Upjohn
• Vaccinex
• W.R. Grace
• Watson Pharmaceuticals
• Wyeth
• Yissum Research & Development Company